Audentes Therapeutics (BOLD) Gets a Buy Rating from Chardan Capital

By Ryan Adsit

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Audentes Therapeutics (BOLDResearch Report), with a price target of $50.00. The company’s shares closed last Monday at $27.84.

According to, Amusa is a 5-star analyst with an average return of 16.2% and a 49.3% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Applied Genetic Technologies, and Catalyst Biosciences Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Audentes Therapeutics with a $37.57 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $41.65 and a one-year low of $17.95. Currently, Audentes Therapeutics has an average volume of 412.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.